Ik zag op de website dat er een buitengewone vergadering is op 18 juli a.s. Daarin is ook onderstaande aan de orde onder punt 1. Iemand een idee wat precies de bedoeling hiervan is, of betreft het een formaliteit? Je zou toch verwachten dat er bij het aangaan van dergelijke overeenkomsten zulke zaken reeds zijn vastgelegd!!
Groet,
Chico
NOTICE FOR THE EXTRAORDINARY GENERAL SHAREHOLDERS MEETING
OF THE COMPANY OF 18 JULY 2013 AT 11AM
The shareholders, the holders of warrants, the Directors and the Statutory Auditor are hereby invited to (i) the Extraordinary General Shareholders meeting of the Company, which will be held on 18 July 2013 at 11:00 CET at the offices of notary Jean-Philippe Lagae, Koningstraat 55/4, 1000 Brussels, before notary Lagae (the “Extraordinary General Shareholders Meeting”), and (ii) if at the Extraordinary General Shareholders Meeting the quorum required to validly deliberate and decide on the items of the agenda would not be reached, a second Extraordinary General Shareholders meeting of the Company would be held on 5 August 2013 at 14:30 CET at the registered offices of the Company with the following agenda containing the motions to vote:
1. Decision to approve, in accordance with Article 556 BCC, certain clauses of the collaboration agreement with Merck & Co
The agreement Ablynx entered into in 2012 with Merck & Co (known as MSD outside the United States and Canada), through a subsidiary of Merck, states that in the event of a change of control over Ablynx, Merck is entitled to elect any one or more of the following options: (i) to immediately discontinue any or all then-ongoing research programs under the agreement; (ii) terminate Ablynx's involvement on any joint committees; (iii) limit Merck's reporting obligations such that Merck is only required to provide reports relating to Merck’s obligation to pay royalties; and/or (iv) if such change of control involves a company that has initiated an IND enabling study for a competing product (i.e. a compound or molecule directed against the same target), to terminate the agreement.
The Board of Directors proposes to approve the above-mentioned clauses in the collaboration agreement with Merck & Co in accordance with Article 556 BCC.